Future Developments in Fibromyalgia Treatment
Philip J. Mease, MD, highlights the potential of blood biomarkers to assist with diagnosing fibromyalgia, as well as other imaging modalities.
EP: 1.Impact of Brain on Nociplastic Pain for Fibromyalgia
EP: 2.Approaching Management of Fibromyalgia and Unmet Needs in Treatment
EP: 3.Current Treatment Options for Fibromyalgia
EP: 4.Treatment Selection and Strategy for Fibromyalgia Agents
EP: 5.Clinical Pearls for the Management of Fibromyalgia
EP: 6.Overview of Fibromyalgia
EP: 7.Challenges for Patients With Fibromyalgia
EP: 8.FDA-Approved Therapies for Fibromyalgia
EP: 9.Treatment Selection in Fibromyalgia
EP: 10.Clinical Pearls for Clinicians Treating Fibromyalgia
EP: 11.Future Developments in Fibromyalgia Treatment
This is a video synopsis/summary of a panel discussion involving Philip J. Mease, MD.
Despite progress in approved medications for fibromyalgia, there are significant unmet needs, such as lack of awareness among patients and clinicians. Education dissemination is crucial to bridge this gap. Additionally, the field anticipates advancements in new therapies, driven by ongoing pain research to unravel pain mechanisms and identify treatment targets. Philip J. Mease, MD, expresses hope for a future with additional treatments beyond the current pharmacological options. Advancements in diagnostic biomarkers, including blood biomarkers to distinguish fibromyalgia from autoimmune diseases, and improvements in neuroimaging for better identification of affected individuals, are also anticipated. These developments hold promise for enhancing understanding and addressing the complexities of fibromyalgia. The speaker emphasizes the importance of these future prospects in advancing fibromyalgia care.
Video synopsis is AI-generated and reviewed by HCPLive editorial staff.
